Adlai Nortye (NASDAQ:ANL) Trading Down 5.5% – What’s Next?

Shares of Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) traded down 5.5% on Thursday . The stock traded as low as $1.55 and last traded at $1.55. 1,683 shares were traded during trading, a decline of 86% from the average session volume of 12,207 shares. The stock had previously closed at $1.64.

Analysts Set New Price Targets

Separately, HC Wainwright lowered Adlai Nortye from a “buy” rating to a “neutral” rating in a report on Monday, June 2nd.

Adlai Nortye Price Performance

The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.02. The business’s 50-day simple moving average is $1.78 and its two-hundred day simple moving average is $2.03.

About Adlai Nortye

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.